659 related articles for article (PubMed ID: 25511639)
21. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
[TBL] [Abstract][Full Text] [Related]
22. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
23. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.
Lu Y; Branstad R; Karim RM; Asinger RW
J Clin Pharm Ther; 2014 Dec; 39(6):628-36. PubMed ID: 25252149
[TBL] [Abstract][Full Text] [Related]
24. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Shah A; Shewale A; Hayes CJ; Martin BC
Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
[TBL] [Abstract][Full Text] [Related]
26. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
[TBL] [Abstract][Full Text] [Related]
27. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
28. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China.
Zhou H; Nie X; Jiang M; Dong W
J Clin Pharm Ther; 2022 Apr; 47(4):523-530. PubMed ID: 34783090
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Liu CY; Chen HC
Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
[TBL] [Abstract][Full Text] [Related]
34. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation.
Micieli A; Wijeysundera HC; Qiu F; Atzema CL; Singh SM
Med Decis Making; 2016 Apr; 36(3):366-74. PubMed ID: 26139448
[TBL] [Abstract][Full Text] [Related]
35. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
36. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Hernandez I; Zhang Y; Saba S
Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
[TBL] [Abstract][Full Text] [Related]
40. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
